Status:

COMPLETED

Determination of a Dose-dependent Effect of GOS on Iron Absorption, and Addition of Vitamin C

Lead Sponsor:

Isabelle Herter-Aeberli

Collaborating Sponsors:

Burgerstein Vitamine

Conditions:

Iron-deficiency

Eligibility:

FEMALE

18-45 years

Phase:

NA

Brief Summary

Iron deficiency is still the most common and widespread nutritional disorder in the world according to WHO. In a recent iron absorption study in adult women with low iron stores in our lab (publicati...

Detailed Description

Iron is an important mineral in our body and fulfills essential functions such as for example oxygen transport from the lungs to the tissues. Iron deficiency is still the most common and widespread nu...

Eligibility Criteria

Inclusion

  • Female, 18 to 45 years old
  • SF levels \<30 µg/L
  • Normal body Mass Index (18.5-24.9 kg/m2)
  • Body weight \<70 kg
  • Signed informed consent

Exclusion

  • Severe anaemia (Hb \< 80 g/L)
  • Elevated CRP \>10.0 mg/L
  • Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
  • Continuous/long-term use of medication during the whole studies (except for contraceptives)
  • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration, including pre- and-or probiotics supplements (excluding foods and beverages with life cultures such as yoghurt, raw milk cheese and kombucha)
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
  • Difficulties with blood sampling
  • Use of antibiotics over the past month
  • Known hypersensitivity to iron supplements in the given amount, GOS, or lactose
  • Women who are pregnant or breast feeding
  • Women who intend become pregnant during the course of the study
  • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, inject-able, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
  • Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse -
  • Smokers (\> 1 cigarette per week)
  • Inability to follow the procedures of the study, e.g. due to language problems, self-- reported psychological disorders, etc. of the participant
  • Enrollment of the investigator, his/her family members, employees and other dependent persons

Key Trial Info

Start Date :

April 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 11 2019

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT03762148

Start Date

April 1 2019

End Date

June 11 2019

Last Update

July 25 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Human Nutrition Laboratory, ETH Zurich

Zurich, Switzerland, 8092